Increased orexin A concentrations in cerebrospinal fluid of patients with behavioural variant frontotemporal dementia.
Cerebrospinal fluid
Frontotemporal dementia
Hypocretin-1
Orexin A
Journal
Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology
ISSN: 1590-3478
Titre abrégé: Neurol Sci
Pays: Italy
ID NLM: 100959175
Informations de publication
Date de publication:
Jan 2022
Jan 2022
Historique:
received:
11
12
2020
accepted:
10
04
2021
pubmed:
28
4
2021
medline:
6
1
2022
entrez:
27
4
2021
Statut:
ppublish
Résumé
Orexins are hypothalamic neuropeptides that regulate several physiological functions, such as appetite, arousal, cognition, stress, sleep and metabolism. Emerging pieces of evidence suggest an orexinergic dysfunction in several neuropsychiatric disorders, including depression, anxiety and addiction. A syndromic overlap between behavioural variant frontotemporal dementia (bvFTD) and several psychiatric disorders was recently demonstrated. Therefore, we analysed cerebrospinal fluid (CSF) orexin A concentrations of 40 bvFTD and 32 non-demented patients, correlating neuropeptide concentrations with several clinical characteristics. A significant increase of orexin A concentrations was found in bvFTD patients when compared to controls (p<0.001). CSF orexin A concentration showed a correlation with Mini-Mental State Examination scores, drug assumption, history of compulsive behaviour and extrapyramidal signs. Moreover, we found a relationship between CSF markers of neurodegeneration, total tau and Aβ
Identifiants
pubmed: 33904007
doi: 10.1007/s10072-021-05250-x
pii: 10.1007/s10072-021-05250-x
pmc: PMC8724071
doi:
Substances chimiques
Orexins
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
313-317Informations de copyright
© 2021. The Author(s).
Références
Bang J, Spina S, Miller BL (2015) Frontotemporal dementia. Lancet 386:1672–1683
doi: 10.1016/S0140-6736(15)00461-4
Chen Q, De Lecea L, Hu Z, Gao D (2015) The hypocretin/orexin system: an increasingly important role in Neuropsychiatry. Med Res Rev 35:1–46
doi: 10.1002/med.21326
Tang H, Zhu Q, Li W, Qin S, Gong Y, Wang H, Shioda S, Li S, Huang J, Liu B, Fang Y, Liu Y, Wang S, Guo Y, Xia Q, Guo Y, Xu Z (2019) Neurophysiology and treatment of disorders of consciousness induced by traumatic brain injury: orexin signaling as a potential therapeutic target. Curr Pharm Des 25:4208–4220
doi: 10.2174/1381612825666191029101830
Liguori C, Mercuri N, Nuccetelli M, Izzi F, Bernardini S, Placidi F (2018) Cerebrospinal fluid orexin levels and nocturnal sleep disruption in Alzheimer’s disease patients showing neuropsychiatric symptoms. J Alzheimers Dis 66(3):993–996
doi: 10.3233/JAD-180769
Piguet O, Petersén A, Yin Ka Lam B, Gabery S, Murphy K, Hodges JR, Halliday GM (2011) Eating and hypothalamus changes in behavioral-variant frontotemporal dementia. Ann Neurol 69:312–319
doi: 10.1002/ana.22244
Liguori C, Romigi A, Mercuri NB, Nuccetelli M, Izzi F, Albanese M, Sancesario G, Martorana A, Sancesario GM, Bernardini S, Marciani MG, Placidi F (2014) Cerebrospinal-fluid orexin levels and daytime somnolence in frontotemporal dementia. J Neurol 261:1832–1836
doi: 10.1007/s00415-014-7455-z
Heywood WE, Hallqvist J, Heslegrave AJ, Zetterberg H, Fenoglio C, Scarpini E, Rohrer JD, Galimberti D, Millsa K (2018) CSF pro-orexin and amyloid-β38 expression in Alzheimer’s disease and frontotemporal dementia. Neurobiol Aging 72:171–176
doi: 10.1016/j.neurobiolaging.2018.08.019
Rascovsky K, Hodges JR, Knopman D, Mendez MF, Kramer JH, Neuhaus J, van Swieten JC, Seelaar H, Dopper EG, Onyike CU et al (2011) Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia. Brain 134:2456–2477
doi: 10.1093/brain/awr179
Doherty CM, Forbes RB (2014) Diagnostic lumbar puncture. Ulster Med J 83(2):93–102
pubmed: 25075138
pmcid: 4113153
Mena JD, Selleck RA, Baldo BA (2013) Mu-opioid stimulation in rat prefrontal cortex engages hypothalamic orexin/hypocretin-containing neurons, and reveals dissociable roles of nucleus accumbens and hypothalamus in cortically driven feeding. J Neurosci 33(47):18540–18552
doi: 10.1523/JNEUROSCI.3323-12.2013
Han Y, Yuan K, Zheng Y, Lu L (2020) Orexin receptor antagonists as emerging treatments for psychiatric disorders. Neurosci Bull 36(4):432–448
doi: 10.1007/s12264-019-00447-9
Chen WY, Kao CF, Chen PY, Lin SK, Huang MC (2016) Orexin-A level elevation in recently abstinent male methamphetamine abusers. Psychiatry Res 239:9–11
doi: 10.1016/j.psychres.2016.02.059
Liu MF, Xue Y, Liu C, Liu YH, Diao HL, Wang Y, Pan YP, Chen L (2018) Orexin-A exerts neuroprotective effects via OX1R in Parkinson’s disease. Front Neurosci 15(12):835
doi: 10.3389/fnins.2018.00835
Thannickal TC, Lai YY, Siegel JM (2007) Hypocretin (orexin) cell loss in Parkinson’s disease. Brain 130:1586–1595
doi: 10.1093/brain/awm097
Wienecke M, Werth E, Poryazova R, Baumann-Vogel H, Bassetti CL, Weller M, Waldvogel D, Storch A, Baumann CR (2012) Progressive dopamine and hypocretin deficiencies in Parkinson’s disease: is there an impact on sleep and wakefulness? J Sleep Res 21(6):710–717
doi: 10.1111/j.1365-2869.2012.01027.x
Zibetti M, Romagnolo A, Merola A, Priano L, Montanaro E, Angrisano S, Tribolo A, Cicolin A, Lopiano L (2017) A polysomnographic study in parkinsonian patients treated with intestinal levodopa infusion. J Neurol 264(6):1085–1090
doi: 10.1007/s00415-017-8491-2
Videnovic A, Golombek D (2013) Circadian and sleep disorders in Parkinson’s disease. Exp Neurol 243:45–56
doi: 10.1016/j.expneurol.2012.08.018
Kang JE, Lim MM, Bateman RJ, Lee JJ, Smyth LP, Cirrito JR, Fujiki N, Nishino S, Holtzman DM (2009). Amyloid-beta dynamics are regulated by orexin and the sleep-wake cycle. Science 13;326(5955):1005-7.